Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization.


Glycosylated natural products are reliable platforms for the development of many front-line drugs, yet our understanding of the relationship between attached sugars and biological activity is limited by the availability of convenient glycosylation methods. When a universal chemical glycosylation method that employs reducing sugars and requires no protection or activation is used, the glycorandomization of digitoxin leads to analogs that display significantly enhanced potency and tumor specificity and suggests a divergent mechanistic relationship between cardiac glycoside-induced cytotoxicity and Na+/K+-ATPase inhibition. This report highlights the remarkable advantages of glycorandomization as a powerful tool in glycobiology and drug discovery.

4 Figures and Tables

Citations per Year

428 Citations

Semantic Scholar estimates that this publication has 428 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Langenhan2005EnhancingTA, title={Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization.}, author={Joseph M. Langenhan and No{\"{e}l R. Peters and Ilia A. Guzei and Francis Michael Hoffmann and Jon S Thorson}, journal={Proceedings of the National Academy of Sciences of the United States of America}, year={2005}, volume={102 35}, pages={12305-10} }